Sentence examples for binding to the natural from inspiring English sources

Finally, to show that Enz is able to regulate transcription factor binding to the natural u-PAR promoter, we performed ChIP analysis for the endogenous u-PAR upstream region.

Antibody binding to the natural MA mixture, as well as several of the synthetic MAs was observed with both TB positive and TB negative patient sera, while some synthetic MAs appeared to have little or no antigenic activity.

This suggests that these two non-catalytic ancillary domains must contain distal sites (i.e. exosites) that are involved in binding to the natural substrates such as aggrecan and versican [ 3].

The presumed function of these agonist drugs is through their binding to the natural cellular receptors of GABA within the neurons of the central nervous system that are located either in the spinal cord or within the brain tissue.

The inhibition of IgE-binding to the natural allergen observed after pre-incubation of the 20 sera with rabbit anti-SlpB-AH3a42 IgG was more than 30% for four sera, more than 20% for eight sera, and below 10% for eight sera.

The more stable photoreactive WT1B-Fbz-bio showed similar binding to both the natural WT1B sequence and the synthetic analog WT1B-S1Y.

From calorimetric experiments, five structural analogues of the natural hapten were estimated to have similar binding affinities to the natural epitope, while one congener displayed very poor binding affinity (Bundle et al. 1994).

All three retinoids were also able to regulate to a similar extent both genes in purified primary Schwann cell cultures (Fig. 7B), although TTNPB was more potent, specially regarding RAR-β up-regulation, indicative of its higher affinity for RAR binding compared to the natural retinoids [32].

The synthetic hydroxy-MAs (Fig. 5), which are the likely precursors of both methoxy- and keto-MA (Yuan and Barry, 1996; Yuan et al., 1997; Asselineau et al., 2002) all attracted weaker antibody binding compared to the natural MA mixture.

Matuzumab is a humanised antibody that competitively inhibits natural ligand binding to the EGF receptor with abrogation of EGFR downstream signalling.

Tamoxifen competes with ERα's natural ligand estradiol for binding to the ligand-binding pocket of the receptor.